Updates are available Correction dated 2025-12-10
Click to view Correction: https://doi.org/10.1038/s41421-025-00862-5
-
Authors
He, Kang https://orcid.org/0000-0003-4671-1337
Zhu, Xue-Jing
Shi, Yao-Ping
Huang, Wei-Jian
Yang, Tai-Hua
Xi, Zhi-Feng
Li, Qi-Gen
Sun, Han-Yong
Qian, Li-Jun
Chen, Xiao-Song
Li, Pei-Ying https://orcid.org/0000-0002-5721-9914
Zhou, Xu
Gu, Gui-Ying
Li, Fan
Liu, Wen-Ming
Chen, Cai-Yang
Zhao, Jie
Wu, Hong-Ping
Yan, Fang-Rong https://orcid.org/0000-0003-3347-5021
Ott, Michael
Sharma, Amar Deep https://orcid.org/0000-0003-3599-2372
Liu, Hui
Yu, Wei-Feng https://orcid.org/0000-0003-1979-6304
Zhai, Bo https://orcid.org/0000-0003-4337-7126
Yan, He-Xin https://orcid.org/0000-0001-8390-650X
Xia, Qiang https://orcid.org/0000-0001-9482-6951
- License Information
-
More Information
Article History
Received: 26 February 2025
Accepted: 19 August 2025
First Online: 5 November 2025
Change Date: 10 December 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41421-025-00862-5
Conflict of interest
: Shanghai Celliver Biotechnology Inc., Ltd. hold patents related to this research, including ZL 2016107094723 (Method for Inducing In Vitro Cholangiocytic Differentiation of Primary Hepatocytes and Their Long-Term Culture, Expansion, and Differentiation, and Applications thereof), and CN2019106234369 (Construction method of liver progenitor-like cell bank, cell lines thereof and application thereof). Xue-Jing Zhu is a full-time employee of Shanghai Celliver Biotechnology Co., Ltd., Shanghai, China. He-Xin Yan is co-founder of Shanghai Celliver Biotechnology Co., Ltd., Shanghai, China and has an interest in Celliver Biotechnology Inc. All other authors declare that they have no competing interests.
